The Effect of Intraoperative Dexmedetomidine on Postoperative Morphine Requirements After Breast Cancer Surgery
Keywords
Abstract
Description
Dexmedetomidine is an α2 receptor agonist with sedative and analgesic properties. In previous reports, dexmedetomidine improves smoothness of postoperative recovery and reduces intraoperatory imflammatory responses. As patients receiving breast surgeries are especially vulnerable to postoperative nausea/ vomiting, the dosage of narcotics and associated complications were concerned for not only comfortness but also postoperative oral intake and discharge.
We aimed to compare the effects of dexmedetomidine infusion versus placebo on postoperative narcotics requirement, complications, and oral intake.
Our patients under general anesthesia and aged from 30 to 65 years old will be enrolled. All subjects were randomized into the dexmedetomidine or placebo group. They received placebo (group P, n = 30) or dexmedetomidine (loading dose of 1 μg kg−1 followed by 0.5 μg kg−1 h−1) (group D, n = 30) to the end of surgery.
Data collected included intraoperative and postoperative opioid consumption. Postoperative questionare including PONV, Pain intensity, I-FEED questionnaire. Prospective analysis will be performed on the prospectively collected data.
We expected to examine if intraoperative dexmedetomidine decreases the postoperative opioid consumption and associated complications, and enhances the gastrointestinal recovery and oral intake with narcotic-sparing effect.
Dates
| Last Verified: | 05/31/2020 |
| First Submitted: | 06/28/2020 |
| Estimated Enrollment Submitted: | 06/29/2020 |
| First Posted: | 06/30/2020 |
| Last Update Submitted: | 06/29/2020 |
| Last Update Posted: | 06/30/2020 |
| Actual Study Start Date: | 07/02/2020 |
| Estimated Primary Completion Date: | 06/30/2023 |
| Estimated Study Completion Date: | 06/30/2025 |
Condition or disease
Intervention/treatment
Drug: dexmedetomidine
Drug: placebo
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: dexmedetomidine patient recieving dexmedetomidine | Drug: dexmedetomidine Dexmedetomidine is an α2 receptor agonist with sedative and analgesic properties. In previous reports, dexmedetomidine improves smoothness of postoperative recovery and reduces intraoperatory imflammatory responses. As patients receiving breast surgeries are especially vulnerable to postoperative nausea/ vomiting, the dosage of narcotics and associated complications were concerned for not only comfortness but also postoperative oral intake and discharge. |
| Placebo Comparator: placebo patients receiving placebo | Drug: placebo normal saline infusion |
Eligibility Criteria
| Ages Eligible for Study | 20 Years To 20 Years |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: - Patients who fulfill the criteria of breast cancer under general anesthesia. Exclusion Criteria: - Major systemic disease, such as congestive heart failure, liver cirrhosis, end stage renal disease and malignancy. - Patients who have the risk of difficult ventilation or intubation. - Pregnant women. - Coagulopathy. |
Outcome
Primary Outcome Measures
1. morphine consumption [postoperative 7 days]
Secondary Outcome Measures
1. I-feeding score [postoperative 7 days]
